← Back to headlines
Halozyme Projects $1.71B–$1.81B Revenue by 2026 with New Subcutaneous Technologies
Halozyme has outlined a revenue target of $1.71 billion to $1.81 billion by 2026, driven by the expansion of its pipeline with new subcutaneous technologies.
18 Feb, 01:25 — 18 Feb, 01:25
Sources
Showing 1 of 1 sources
Related Stories
August Manufacturing PMI Data Reveals Divergent Global Economic Performance
28m ago
Shein’s Hong Kong IPO Debut Underwhelms Amid Geopolitical Risks and New Fashion Levies
29m ago
Wall Street Futures Drop as Rising Yields and Oil Prices Weigh on Markets
44m ago
IKEA Launches €1.2 Billion Price Cut Campaign Across Europe
49m ago